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Cell killing by the novel imidazoacridinone antineoplastic agent, C-1311, is
inhibited at high concentrations coincident with dose-differentiated cell
cycle perturbation
J Lamb and DN Wheatley
Cell Pathology Unit, University Medical School, Foresterhill, Aberdeen AB9 2ZD, UK.
Summary We have studied the actions of C-1311, an imidazoacridinone analogue with potent in vivo anti-
tumour activity, against a human tumour line (HeLa S3), in an examination of the events associated with the
lethality of this agent. Continuous exposures (24 h) induced complete G2 arrest, although the concentration
range of this effect was narrow, with elevation of the drug level inducing additional and increasing impediment
to S-phase transit. Acute treatments (3 h) revealed that cells exposed to drug levels, which first induced
persistent G2 arrest (0.5 jug ml-1), subsequently died from this compartment, while doses exceeding these levels
(1.0 ig ml-'), paradoxically, did not cause the same extensive cell death. We explain our findings on the
proposition that this particular mode of cell death is dependent upon inappropriate activation of the primed
mitotic machinery-specifically the hyperphosphorylated p34cdc2/cyclin B complex-assembled within G2, but
that impediment to genomic replication at higher doses inhibits assembly of this complex, and hence prevents
cell death. Our results demonstrate that high dose does not necessarily correlate with increased cell death, while
at the same time providing further evidence for the importance of events normally associated with the G2/M
transition in DNA damage-induced tumour cell death.
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Imidazoacridinones constitute a new class of antineoplastic
agent, whose major representatives (including the lead
compound designated C-1311) possess potent anti-tumour
activity against a range of murine neoplasms (Cholody et al.,
1992; Kusnierczyk et al., 1994) and human tumour
xenografts in nude mice (Augustin et al., 1996), in addition
to significant in vitro cytotoxicity against both murine
leukaemia cells (Cholody et al., 1992) and the human
tumour lines of the National Cancer Institute (NCI) screen.
C-1311 has recently been accepted for clinical trials in the
UK.
Recent in vitro studies have identified the imidazoacridi-
nones as topoisomerase II poisons (Skladanowski et al.,
1996), and three major representatives (C-1311, C-1310,
C-1263) have been shown to be potent inhibitors of L1210
(murine leukaemia) cell cycle progression, causing selective
accumulation in the G2 phase (i.e. G2 block) (Augustin et al.,
1996). This cellular response is universally associated with the
action of DNA-damaging agents, including the topoisome-
rase II inhibitors (Kimler et al., 1978; Konopa, 1988; Lock
and Ross, 1990a; O'Connor et al., 1991; Sorenson and
Eastman, 1988b; Tounekti et al., 1993), and represents
activation of a DNA damage cell cycle checkpoint, whose
engagement delays segregation of damaged chromosomes,
thereby preventing mitotic catastrophe, and affording the cell
opportunity for repair (Al-Khodairy and Carr, 1992;
Hartwell and Weinert, 1989; Murray, 1994; Murray, 1992;
Weinert and Lydall, 1993). The biochemical basis of this
cytostatic effect is relatively well understood, although the
mechanism by which these agents actually effect cell killing,
in which anti-tumour activity resides, remains comparatively
obscure.
Reports of rapid or immediate cell death secondary to
exposure to DNA-damaging agents (i.e. cell death without
prior cycle arrest) have been made. However, these events are
apparently restricted to cell types with a particular propensity
for this response (Bertrand et al., 1991b, 1993; Del Bino et
al., 1990; Kaufmann et al., 1989; Radford et al., 1994), or
dependent upon the integrity of a p53-dependent pro-
grammed cell death pathway (Clarke et al., 1993; Lowe et
al., 1993), which is itself only manifest in certain, mainly
lymphoid, cell types (Fan et al., 1994; O'Connor et al., 1993b;
Slichenmyer et al., 1993).
The appearance of cells arrested in the G2 phase has been
shown to precede cell disintegration in many cell lines
exposed to various DNA-damaging agents (Evans and
Dive, 1993; Kim et al., 1993; Kruman et al., 1991; Lock
and Ross, 1990b; Ormerod et al., 1994; Skladanowski and
Konopa, 1993; Sorenson and Eastman, 1988a; Warters, 1992;
Yamagishi et al., 1993), suggesting that cycle arrest is an
essential intermediate in drug action. Consequently, consider-
able importance has been placed upon the role of events
normally associated with the G2/M transition in the death
mechanism (Barry et al., 1990; Bertrand et al., 1991a;
Eastman, 1990; Fotedar et al., 1995; Rubin et al., 1993; Shi
et al., 1994; Sorenson et al., 1990), leading to the proposition
that inappropriate or aberrant mitotic events may actually
cause cell death.
The G2/M transition is universally controlled in mamma-
lian systems by p34cdc2 kinase (Norbury and Nurse, 1992), the
activity of which is principally regulated by association with
cyclin B (Pines and Hunter, 1989) and a complex series of
phosphorylation/dephosphorylation reactions (Draetta and
Beach, 1988). Cyclin A is also implicated in association with
both p34cdc2 and one of a family of related protein kinases
(Meyerson et al., 1992), identified as p33cdk2 (Elledge et al.,
1992; Rosenblatt et al., 1992). Mitotic progression is
ultimately achieved by final activation of the p34cdc2/cyclin B
complex through dephosphorylation ofp34cdc2 at threonine 14
and tyrosine 15, and it is inhibition of this tyrosine
dephosphorylation (Lock, 1992; Lock and Keeling, 1993;
O'Connor et al., 1993a), with concomitant suppression of
p34CdC2 kinase activity (Lock and Ross, 1990a; O'Connor et al.,
1992; Tsao et al., 1992), which effects the premitotic cell cycle
arrest induced by DNA-damaging agents.
At the molecular level, the proposition that (aberrant)
mitotic events cause cell death is amply supported by recent
evidence. Activation (tyrosine dephosphorylation) of p34cdc2
kinase at inappropriate times during the cell cycle leads to
cell death (Shi et al., 1994). Overexpression of cotransfected
p34CdC2 and cyclin B in BHK cells induces mitotic catastrophe
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(Heald et al., 1993) and comparable ectopic expression of this
cyclin-kinase complex in HeLa cells results in DNA
fragmentation and cell death, while cyclin B-specific
antisense oligonucleotides can suppress the lethal transition
(Fotedar et al., 1995). Similarly, activation of p34cdc2 and
p33cdk2 by methylxanthines and purine analogues induces cell
death in arrested HeLa cells, the effect being accompanied by
an increase in histone HI kinase activity to near mitotic levels
(Meikrantz et al., 1994).
Indeed, the release of cells from DNA damage-induced G2
arrest into cell death is accompanied by an increase in p34cdc2
kinase activity (Lock and Keeling, 1993; Lock and Ross,
1990b) and is promoted or potentiated by the same agents
known to cause premature mitosis, whose actions enhance
p34Cdc2 tyrosine dephosphorylation (Crompton et al., 1993;
Hain et al., 1993; Lock et al., 1994; Steinmann et al., 1991;
Tam and Schlegel, 1992). It seems likely then that this
particular mode of cell death: (1) is dependent upon assembly
of the primed mitotic machinery, specifically the hyperphos-
phorylated p34cdc2/cyclin B complex; and (2) reflects a failure
of the G2 checkpoint to maintain a premitotic arrest in a
circumstance where cell cycle progression is incompatible
with cellular survival.
That DNA damage-induced cell death is dependent upon
the assembly of the hyperphosphorylated p34cdc2/cyclin B
complex associated with G2 phase, has considerable
significance and clinical implication. It is known that the
range of drug concentrations causing 'pure' G2 block is very
narrow. An increase in levels beyond that producing G2
accumulation additionally induces S-phase arrest (Konopa,
1988); a stage in cycle before the assembly of the mitotic
machinery. We, therefore, set out to characterise the cell cycle
perturbations induced by C-1311 across a wide concentration
range, and then to examine the cellular responses and
treatment outcomes subsequent to these different primary
cycle perturbations.
Our results show that, as predicted, drug levels exceeding
those which induce a G2 arrest effectively inhibit cell killing,
demonstrating that high dose does not necessarily correlate
with increased cell death, while at the same time providing
further evidence for the role of events normally associated
with the G2/M transition in the cell death process.
Materials and methods
Drugs, reagents and chemicals
C-1311 (synthesised at the Technical University of Gdansk,
Poland) was stored at 4°C as a stock solution (50 pg ml-' in
phosphate-buffered saline (PBS); filter sterilised). RPMI-1640
and Dulbecco's modified Eagle (DME, 4500 mg l-l glucose
modification) media were obtained from Gibco/BRL (Life
Technologies Ltd., Paisley, UK). Calf serum was from
Advanced Protein Products Ltd. (Brierley Hill, UK) and
benzylpenicillin from Britannia Pharmaceuticals Ltd. (Red-
hill, UK). Streptomycin sulphate, spermine tetrahydrochlor-
ide, tris(hydroxymethyl)aminomethane, trypsin, trypsin
inhibitor, ribonuclease A, propidium iodide, 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyI tetrazolium bromide (MTT),
and isopropanol were purchased from Sigma. Nonidet P40
and dimethyl sulphoxide (DMSO) were from BDH Chemicals
Ltd. (Poole, UK), and crystal violet from Raymond A Lamb
(London, UK).
Cell culture
HeLa S3 (human cervical epithelial carcinoma) cells were
cultured as a monolayer in RPMI-1640 supplemented with
10% calf serum and antibiotics (100 pug ml-1 streptomycin,
100 U ml-' penicillin) at 37°C in a humidified 5% carbon
dioxide atmosphere. Under these conditions, the population
doubling time was approximately 24 h. Primary human
diploid fibroblasts (RMF/), derived from neonatal foreskin
samples, were maintained in monolayer in DME supplemen-
ted with 10% calf serum and antibiotics as above. Cells from
passages 6 to 10 were used in these studies. Cells were
provided by BioCuRe Ltd. (Aberdeen, UK).
Drug treatments
A series of C-1311 working solutions were prepared from
stock, with PBS as diluent, immediately before use. Samples
(100 pl) of each, added directly to a culture (or to 2 ml of
culture medium), achieved the specified final concentrations.
Control cultures received an equivalent solvent exposure.
Cells were grown in 6-well culture plates from a seeding
density of -1 x 105 (HeLa) or - 5 x I04 (RMF/) cells per well
(in 2 ml of culture medium) for 24 h before drug addition.
Cultures were dosed as described. After drug exposure,
cultures were either submitted for analysis or the culture
medium aspirated, the monolayer washed with prewarmed
PBS and incubation continued in fresh medium for up to a
total of 96 h, at which point the same analyses were
conducted.
Flow cytometry
Cells were harvested by gentle trypsinisation and combined
with any non-adherent cells contained within the aspirated
medium, which also served to neutralise the trypsin action.
The cells were collected by centrifugation (400 g, 5 min) and
resuspended in PBS. An aliquot of this suspension was
further diluted with PBS and submitted for cell sizing; 5000
cells were analysed. Nuclei from the remainder of the
suspension were isolated and stained with propidium iodide
by the method of Vindel0v et al. (1983). Nuclear fluorescence
(DNA content) and forward light scatter (cell or nuclear
volume) were recorded for each population, with doublet
discrimination, using an EPICS Profile-II flow cytometer
(Coulter Electronics Inc., Hialeah, FL, USA). The number of
nuclei present in each (constant volume) sample was counted
(concurrent with fluorescence and light scatter recordings) to
give an indication of the cell density in each culture. Not less
than 10 000 nuclei were processed per sample. Cell cycle
phase distributions and the number of sub-G, events
(expressed as a percentage of total events) were obtained,
as necessary, by decomposition of single parameter DNA
content frequency histograms using the 'Cytologic' software
package (Coulter Electronics Inc.).
Growth inhibition assay
Cells were grown in 6-well culture plates for 24 h from a
seeding density of - 5 x 104 cells per well. Cultures were
dosed as described and incubation continued for a further
72 h, at which point the culture medium was removed, the
monolayers washed with prewarmed PBS, and the cells
harvested by gentle trypsinisation. Cell number was
determined with a Model ZM Coulter Counter (Coulter
Electronics Inc.) and the percentage of growth inhibition was
calculated as follows, after the method of Bhuyan et al.,
(1992): 100-100 x [(cell number in treated well-cells
inoculated) (cell number in control well-cells inoculated)].
The 50% growth inhibitory concentration (IC50) was
determined by interpolation of the resultant dose-response
curves.
Clonogenic survival assay
Reproductive capacity was assessed by colony-forming assay.
Cells in exponential growth were washed twice with
prewarmed PBS and resuspended in growth medium. Cell
density was determined and adjusted such that a known
number (- 1000 cells) were seeded into each well of a 6-well
culture plate in 2 ml of medium. Cells were allowed to grow
for 24 h before being dosed as described. After 3 h drug
exposure, the medium was removed and the cells washed with
prewarmed drug-free medium. Fresh medium was added andincubation continued for a further 5 days. Colonies were
stained with 2% crystal violet in methanol and counted.
Reproductive capacity was expressed as a percentage of the
cloning efficiency of controls.
MTT cleavage assay
Cell survival was assessed by MTT cleavage assay (Mosmann,
1983). Cells were seeded in 96-well culture plates at -4000
cells per well in 100 ,ul of growth medium and incubated at
37°C for 24 h, at which time the medium was removed and
replaced by complete medium (100 ,ul) containing C-1311.
After 3 h, the medium was aspirated and the monolayers
washed with prewarmed PBS. Fresh medium (100 ,ul) was
added to each well and incubation continued for a further
93 h. MTT solution (10 ,ul) (5 mg ml 1'in PBS, filter sterilised)
was added to each well and incubation continued for a further
4 h at 37°C. The formazan product was solubilised by the
addition of 100 jMl of 0.04 M hydrochloric acid in isopropanol.
The optical density of each well was measured using a
Dynatech MR5000 plate reader at a wavelength of 570 nm
with background subtraction at 690 nm. Wells containing
culture medium and MTT but no cells acted as blanks. Cell
survival was expressed as a percentage defined by:
[(drug -blank) . (control -blank) x 100].
Results
Growth inhibition and cell cycle perturbations following
continuous exposure
Dose-dependent inhibition of HeLa S3 cell growth was
observed after 72 h continuous exposure to C-1311 (Figures 1
and 2). The IC50 was calculated as 0.018+0.003 jg ml-'
(n =4). This value is in broad agreement with the work of
Cholody et al. (1992) and Augustin et al. (1996), and
indicates that HeLa and L1210 murine leukaemia cells share
a similar sensitivity to the growth-inhibitory activity of the
compound.
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Figure 1 Structural formula of the substituted aminoimidazoa-
cridinone designated C-1311.
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Figure 2 The growth-inhibitory effect of 72 h continuous
treatment with C-1311 on HeLa S3 cells. Each dose-response
curve represents an independent experiment.
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The influence of C-1311 on the cell cycle progression of
exponentially growing asynchronous cultures of HeLa cells
was assessed after continuous exposure to a wide range of
drug concentrations. Histograms representing the distribution
of cells through the cycle after a 24 h exposure are shown as
Figure 3a and the corresponding cell cycle phase distributions
are presented as Table I.
Cultures treated with C-1311 at 0.01 i,g ml-' showed only
a marginal deviation from control cell cycle distribution.
Exposure to C-1311 at 0.05 ,ug ml-' induced a conspicuous
perturbation of cell cycle progression, however. A marked
increase in the proportion of cells with a G2 phase character,
and a significant reduction in cell number over control was
observed, defining a G2 phase accumulation. Given that
exposure time was selected to be marginally greater than
cycle time, it was supposed that the observed G1 population
was derived from cells having recently made the G2/M
transition, and having passed the G2 accumulation point,
signifying either that G2 transit time was extended, the
progression delay was of a finite duration, or that some cells
did not arrest at the accumulation point (i.e. an incomplete
or 'leaky' cell cycle arrest). No slowing of S-phase transit was
apparent. Treatment at 0.1 jug ml-' yielded a culture
composed almost entirely of cells with G2 phase character.
This, together with the albeit total absence of cells from the
G, and S-phases indicated a complete and preferential G2
arrest. Elevation of drug levels beyond this concentration
resulted in the induction of an additional S-phase accumula-
tion, with increasing concentration producing accumulations
earlier in phase.
Exponentially growing asynchronous cultures of normal
human diploid fibroblasts were continuously exposed to
C-1311 for 48 h. The agent induced the same sequence of
cycle perturbations, and at similar concentrations, as in HeLa
cells, although in all cases a G1 phase arrest accompanied the
late cycle accumulations (Figure 3b; Table II). Nuclear and
cellular volume distributions were consistent with the
reported perturbations of cell cycle (data not shown).
Treatment outcomes following acute exposures
Exponentially growing HeLa S3 cultures were exposed to
C-131 1 at concentrations of 0.01 - 1.0 jug ml - for 3 h, before
transfer into drug-free medium for up to a total of 96 h.
Histograms of nuclear DNA content obtained throughout
this treatment matrix are shown as Figure 4.
While untreated cultures exhibited typically unperturbed
DNA content distributions throughout the course of the
experiment, treatment with C-1311 at 0.01, 0.05, or
0.1jIg ml-' induced modest late cycle phase accumulations,
which were maximal at 12 h. These cultures recovered
control cell cycle distributions within the time course of
the experiment and cell number increased correspondingly.
These cultures were subject to a transient or incomplete G2
block, which was rapidly overcome, thus representing only a
minor impediment to expansion of the culture. Exposure to
C-1311 at 0.5 ,ug ml-1 induced an overt and progressive
disturbance of cell cycle distribution, however. Almost
complete absence of cells with a G, character at 12 h
signified a strict G2 block, confirmed by an all but 'pure' G2
population at 24 h. By 48 h, this arrested population was
accompanied by considerable nuclear debris (sub-G1 signal)
signifying extensive degradation of the culture. All cells
arrested in G2 phase at 48 h were subsequently lost, such
that by 96 h only nuclear debris remained. Treatment at a
concentration of 1.0 jMg ml-' also produced frank perturba-
tions of cell cycle distribution, but with a markedly different
outcome. In contrast to treatment at 0.5 jug ml-', these
cultures were composed predominantly of S-phase cells at
24 h and, although these cells attained approximate G2
DNA content character within a further 24 h, the absence
of nuclear debris at this time was striking. Indeed, by the
end of the experiment (96 h), there was only limited evidence
of cellular disintegration. Cell and nuclear volume distribu-Am "ft Concentration dependent lethality of C-1311
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Figure 3 Histograms representing the distribution of (a) HeLa S3 cells and (b) normal human diploid fibroblasts (RMF/) through
the cell cycle following continuous treatment with C-1311 for 24h or 48h respectively. Each histogram is a plot of nuclear DNA
content against frequency. T represents 2n DNA content,A represents 4n DNA content. These data were obtained from a single
experiment but are representative of (a) five and (b) three independent experiments.
Table I Cell cycle phase distributions of HeLa cells treated
continuously for 24h with various concentrations of C-1311. These
cell cycle phase fractions were derived from the DNA content
frequency histograms shown in Figure3a
C-1311 concentration Percentage of cells (igmr G) S G2/M
Control 58 27 15
0.01 49 27 23
0.05 28 11 61
0.1 3 0 97
0.5 2 60 38
1.0 3 57 40
Table II Cell cycle phase distributions of normal human diploid
fibrobalsts (RMF/) treated continuously for 48h with various
concentrations of C-1311. These cell cycle fractions were derived
from the DNA content frequency histograms shown in figure3b.
C-1311 concentration Percentage of cells
(mgml') GI S G2/M
Control 75 12 13
0.05 66 0 34
0.1 63 3 34
0.25 62 8 29
0.5 60 11 29
1.0 59 17 24
tions, and microscopic examinations were consistent with
these findings (data not shown). Cell death superficially
resembled apoptosis (appearance of small, rounded,
refractile bodies) but a panel of techniques for identification
of the features of this form of cell death together failed to
provide unequivocal confirmation. On this point we concur
with the sentiments of Darzynkiewicz (1995) that cell death
from the G2 compartment often resembles apoptosis,
although it frequently lacks all the classical features of the
latter.
Reproductive capacity and cellular survival at 96 h, as
assessed by colony-forming ability and MTT cleavage
following the same drug exposures, were examined in
parallel with this flow cytometric analysis. Reproductive
capacity was reduced in a dose-dependent manner, with no
cells forming colonies after treatment at drug concentrations
of 0.5 jug ml-' and above (Figure 5). In contrast, cell survival
was reduced in a dose-dependent fashion to a minimum at
0.5 ,g ml-' but, beyond this level, the typical sigmoidal
profile was inflected, and survival was significantly enhanced
from this minimum (Figure 6).
A further series of flow cytometric experiments were
conducted, in which exposure to C-1311 was extended to 6,
12 and 24 h before transfer to drug-free medium. Essentially
a-
t +the same sequence of events was mirrored in these
circumstances, although at these extended exposure times,
cellular disintegration was apparent at lower drug levels and
Control
0.01 ,ug ml 1
0.05 gg ml 1
0.1 jgml1
0.5 jg ml 1
1.0 gml m1
6 h 12 h
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became manifest more rapidly. Cellular persistence was also
seen at correspondingly lower drug levels. The dual
parameters of dose and exposure time were important in
24 h 48 h 96 h
Figure 4 Histograms of nuclear DNA content for HeLa S3 cells acutely treated with C-1311. Following drug exposure (0-
1.Ojugml-l for 3h), cells were incubated in drug-free medium for the indicated intervals up to a total of 96h. Number of sub-GI
events (expressed as a percentage oftotal) for each histogram is given where>3%. Details as Figure 3. Each treatment was repeated
at least once.
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Figure 5 Reproductive capacity of HeLa S3 cells exposed to
C-1311 for 3 h as assessed by colony-forming assay. Cloning
efficiency of untreated (control) cells was 25-30%. Each point
represents the mean of two independent determinations.
Figure 6 Survival of HeLa S3 cells exposed to C-1311 for 3h
before transfer to drug-free medium to a total of 96h. Cell
survival was assessed by MTT cleavage assay. Each point
represents the mean of six replicate determinations +standard
deviation. Control OD570-690 was 0.985+0.031. These data were
obtained from a single experiment but are representative of three
independent experiments.
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determining the treatment outcome. In demonstration of this
effect, Figure 7 presents photomicrographs of HeLa cultures
exposed to C-1311 over a concentration range from 0.01 to
1.0 jug ml-1 for 24 h before transfer into drug-free medium
for only a further 24 h. Considerable detachment of cells
from the monolayer, which we associate with cell death, was
apparent in cultures dosed at 0.05 jig ml-' and extensive at
0.1 ,ug ml-1 (Figure 7c and d). Cultures exposed to greater
drug concentrations (0.5 and 1.0 ,g ml-'), although com-
posed of apparently enlarged and misshapen cells, exhibited
no 'rounded' or detached bodies and appeared relatively
healthy (Figure 7e and f). We note with interest that cultures
dosed at these higher levels remained largely free of cell
disintegration even after a further 72 h in drug-free medium
(data not shown).
Discussion
We have studied the actions ofC-1311, the lead compound in
a new class of imidazoacridinone antineoplastic agents,
against a human tumour line (HeLa S3), in an examination
of the events associated with the lethality of these agents.
First, we examined the sequence of dose-dependent cell
cycle effects induced by C-1311 and found them to be typical
of a DNA-damaging agent and consistent with the
established pattern of cell cycle checkpoint engagement. We
demonstrated that C-1311 can induce a complete preferential
'pure' G2 accumulation (i.e. G2 arrest) in HeLa cultures,
representing the action of a DNA damage cell cycle
checkpoint, but that the concentration range of this effect is
very narrow, with elevation of the drug level inducing
4',
_
Figure 7 Phase contrast photomicrographs of HeLa S3 cultures exposed to C-1311 at (a) control, (b) 0.01, (c) 0.05, (d) 0.1, (e) 0.5
and (f) 1.0ygml-1 for 24h before transfer to drug-free medium for a further 24h. Bar=501tm.additional and increasing S-phase accumulation (Konopa,
1988), more likely caused by a physical impediment to
genomic replication than to an active response mechanism
(Fornace, 1992; Liu, 1989). This sequence of events is similar
to, and induced at similar drug levels as, those observed
against the L1210 murine leukaemia line (Augustin et al.,
1996), and is, therefore, consistent with our finding that the
sensitivity of the L1210 line to (the growth inhibitory activity
of) the compound reported by others (Cholody et al., 1992) is
shared by the HeLa line.
We have also shown that normal human diploid
fibroblasts (which putatively express wild-type p53 tumour-
suppressor gene) exposed to C-1311 exhibit the same
sequence of cycle perturbations, and at similar concentra-
tions as HeLa cells, although in all cases a G1 phase arrest
accompanied these late cycle accumulations. This observation
is consistent with the demonstration that cells which express
wild-type p53 exhibit both GI and G2 arrest after exposure to
DNA-damaging agents, whereas those which lack p53
expression, express a mutant form of the p53 gene, or fail
to accumulate p53 protein (as do HeLa cells), typical of many
tumour cell lines (Hollstein et al., 1991; Levine et al., 1991),
arrest only in G2, reflecting loss of the GI DNA damage-
sensitive cell cycle checkpoint (Fritsche et al., 1993; Kastan et
al., 1991, 1992; Kuerbitz et al., 1992).
An identical sequence of cycle perturbations was exhibited
by cultures of HeLa cells and normal fibroblasts treated with
the recognised topoisomerase II inhibitor, etoposide (Liu,
1989), albeit at 10-fold higher concentrations than with
C-1311 (unpublished observations).
Cell cycle arrest is not a biological end point, however,
and it is the fate of the arrested cell which determines the
ultimate treatment outcome. Flow cytometric analysis of
cellular DNA content can reveal both cell cycle position and,
as judged by the appearance ofcells with a less than G, DNA
content, nuclear disintegration. While quantitation of sub-GI
events does not give an absolute measure of cell death, since
more than one recordable fragment may result from
disintegration of a single cell, this technique does provide a
rapid method for the simultaneous analysis of the kinetics of
cell cycle perturbation and cell death. In this way we
demonstrated that HeLa cultures acutely exposed to doses
of C-1311 that induce a preferential and persistent G2 arrest,
subsequently undergo cell death from this compartment. This
is in accordance with numerous empirical reports, which
identify arrest in this phase as an immediate precursor to cell
death induced by chemotherapeutic DNA-damaging agents
(see Introduction for references). Additionally, however,
doses exceeding the narrow range in which 'pure' G2
accumulations were generated, paradoxically, did not result
in the same extensive cell death. Instead these cultures,
initially composed predominantly of S-phase cells, remained
relatively healthy, showing comparatively little of the cellular
disintegration and death so striking in their cohort cultures.
Cellular survival assessments made by MTT cleavage
assay, which relies upon the ability of live (but not necessarily
proliferating) cells to convert a soluble component to an
insoluble and readily quantifiable coloured product through
the action ofmitochondrial dehydrogenase (Mosmann, 1983),
clearly reflected the enhanced survival of cultures exposed to
high doses of compound, relative to treatments at lower
levels, as did two other independent metabolic measures:
neutral red uptake and [3H]leucine incorporation (data not
shown). Clonogenic assays cannot discriminate between
arrested cells which do not form colonies and those which
are killed outright (Lanks and Lehman, 1990); taken
together, these observations identify the surviving population
as non-reproductive, but metabolically active.
We consider our findings entirely consistent with the
proposition that events normally associated with the G2/M
transition are implicated in the mechanisms of cell death, and
indeed provide further evidence in its support. That cell death
is associated with activation (dephosphorylation) of the
p34CdC2 kinase distal to G2 arrest (Lock et al., 1994; Lock
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and Keeling, 1993; Lock and Ross, 1990b), suggests that this
particular mode of cell killing is dependent upon assembly of
the primed mitotic machinery, specifically the hyperphos-
phorylated p34cdc2/cyclin B complex. This mechanism relies,
therefore, upon cell cycle progression being allowed to
proceed to the temporal location of complex assembly.
Given that human cells synthesise cyclin B and form p34`dc2
complexes comparatively late in cycle (Steinmann et al.,
1991), cellular derangements which prevent progression to
this point, such as the impediment to genomic replication
owing to high doses of DNA-damaging agents observed in
this study and by others (Konopa, 1988), will prevent
assembly of the complex. Although cellular damage
secondary to pharmacological insult may be more severe,
cell death induced by kinase activation is prevented, just as
by artificial inhibition of complex assembly by cyclin B
antisense oligonucleotides (Fotedar et al., 1995).
Cells treated with high drug levels, which initially
exhibited an S-phase delay, and appeared protected from
cell death, did eventually attain G2 DNA content but still did
not succumb. Instead we found a tendency to initiate a
second round of DNA synthesis in the absence ofmitosis (see
>G2 cells Figure 4, 1.0 ug ml-l at 48 h and 96 h), similar to
behaviour exhibited by cells surviving doxorubicin exposure
(Lanks and Lehman, 1990). It is reported that HeLa cells
subject to inhibition of DNA synthesis also down-regulate
protein synthesis due to a strict integrational coupling
between nuclear and cytoplasmic events, and hence do not
accumulate cyclin B when so arrested (Kung et al., 1993). It
may be that excessive delay in genomic replication is
associated with an inability to accumulate sufficient levels
of the protein for mitosis (or cell death), resulting in survival
and entry to the higher ploidy state observed. Studies are
underway to confirm directly the failure of these cells to
accumulate or associate cyclin B and p34`dI2*
Application of our findings to the clinical exploitation of
DNA-damaging chemotherapeutic agents suggests that
maximum anti-tumour efficacy can only be attained within
a narrow dose range, and that doses in excess of this level
may not confer any advantage in terms of tumour cell kill.
Cells surviving a DNA damage insult, which presumably
harbour a pool of induced genetic mutations, can regain
proliferative capacity (Sorensen and Eastman, 1988b) but
may also become 'adapted' to their lesions and resume cell
cycle progression before completion of repair (Weinert and
Lydall, 1993). The treatment thus becomes associated with an
enhanced probability that more malignant or drug-resistant
clones will appear, and hence with a poorer outcome. Only
those treatments which culminate in frank tumour cell death
are compatible with the pursuit of selective antineoplastic
chemotherapy.
It is still unclear whether cell death associated with mitotic
kinase activation results directly from failure to execute a
normal mitosis, and whether in some circumstances this
mitotic catastrophe merely resembles programmed cell death
(i.e. by causing the features of apoptosis), or if proteins
phosphorylated by p34Cdc2/cyclin B are positive mediators of a
true, specific, inducible cell death programme. The latter is
predicted by a modification of the 'dual signal' hypothesis
(Evan and Littlewood, 1993), in which progressional control
events simultaneously activate both the proliferative process
and a cell death mechanism as a 'fail safe' against
uncontrolled or inappropriate proliferation. Relaxation of
the normal downstream inhibition of the cell death
programme, on detection of unrepaired genomic damage,
provides a physiological suicide response after checkpoint
failure rather than death as a consequence of mitosis
attempted in the presence of critical damage with the
attendant danger of survival with gross chromosomal
derangement.
What is clear, however, is that this pathway frequently
constitutes the predominant route to the death of tumour
cells, at least in vitro, following induced DNA damage.
Whatever the detail, downstream failure of the premitoticAP4 Concentration dependent lethality of C-1311
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checkpoint-leading to inappropriate or premature kinase
activation-is an important initial feature of this mechanism.
The 'proliferative impetus' gained in transformation through
overexpression of the positive regulators of cell cycle control,
p34cdc2 and cyclin B (Oshima et al., 1993; Steinmann et al.,
1994), which shift the balance in regulation away from the
antiproliferative signals derived from DNA damage, with
concomitant attenuation of G2 checkpoint function (Kauf-
mann et al., 1995), facilitates the genetic instability
characteristic of cancer (Hartwell and Kastan, 1994;
Hartwell, 1992; Weinert and Lydall, 1993), but also
predisposes these cells with a vulnerability to DNA
damage. Given, additionally, that checkpoint function
appears inversely related to increasing transformed pheno-
type (Kung et al., 1990), recent indications that cells with
defective p53 are more susceptible to G2 checkpoint
abrogation (Fan et al., 1995; Powell et al., 1995; Russell et
al., 1995), and the marked susceptibility of the highly
deranged HeLa line (this study), future work will attempt
to correlate G2 checkpoint stringency with sensitivity to
DNA-damaging agents to examine possible differential
lethality towards tumour cells.
It has recently been demonstrated that G, arrest mediated
by superimposition of wild-type p53 function upon a
transformed cell line markedly reduced the extent of DNA
damage-induced cell death, coincident with a decrease in the
proportion of cells reaching the G2 phase (Malcomson et al.,
1995), and that abolition of G, arrest through disruption of
normal p53 function sensitised a human cancer line to DNA
damage, coincident with an increase in the proportion of cells
reaching G2 (Fan et al., 1995). These findings further
highlight the importance of G2 checkpoint targeting for
maximum chemotherapeutic advantage, especially in cell
types which do not exhibit a propensity to undergo p53-
dependent programmed cell death. On this basis, the
influence of G, checkpoint fidelity upon the prevalence of
cell killing from the G2 compartment will also be examined in
terms of both chemoresistance of tumour cells, and
protection of normal cells, like the fibroblasts in this study,
from deleterious consequences of exposure to these noxious
agents.
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